SynthesisBMJ open2016

Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis.

Shu Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.